Twitter

Chordate interview: CEO Anders Weilandt on the new trademark – Ozilia™

Biostock interviews Chordate Medical’s CEO Anders Weilandt about the new Ozilia™ brand, which is the next step in the commercialization project of the company’s migraine treatment, and which will be launched at the International Headache Congress in Seoul September 14-17.

 “It will be incredibly exciting to present Ozilia and our unique technology for preventive migraine treatment without drugs. The global leaders in migraine care, research and industry are gathered at this congress, which is our first international exhibition. Our expectation is to be able to create many good contacts to support the commercialisation project.  

Read the full article

More posts

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia™ Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

The information is handled according to our privacy policy

Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical’s share is listed on the Nasdaq First North Growth Market (ticker: CMH).

Press releases

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Privacy policy

Twitter